Contact us

877-469-1TRM
424-208-8866

Study Evaluating the Efficacy, Safety and Pharmacokinetics in Patient With T790M-positive Non-small Cell Lung Cancer (NSCLC)

A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive Non-small Cell Lung Cancer After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor.

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
NSCLC HM61713 II Open and Accruing